Previous Close | 89.33 |
1-Year Change | 74.03% |
6-Months Change | 1.21% |
3-Months Change | -15.09% |
Moving Avg (50d) | 99.23 |
Moving Avg (200d) | 94.169 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 5.43B |
Beta (3-Years) | 1.27 |
Revenue Growth (ttm) | -20.59% |
Net Profit Margin (ttm) | -256.57% |
Return On Assets (ttm) | -50.19% |
EPS (ttm) | -9.19 |
PE Ratio (ttm) | -9.72 |
Dividend Yield | % |
Asset Description: | Blueprint Medicines Corporation |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-09-16 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
87.543 | 84.864 | 83.077 | 80.397 | 75.931 | 71.464 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.